NEW

FDA clears first fully disposable duodenoscope, eliminating the potential for infections caused by ineffective reprocessing

The U.S. Food and Drug Administration today cleared for marketing in the U.S. the first fully disposable duodenoscope. The EXALT Model D Single-Use Duodenoscope is intended to provide visualization and access to the upper gastrointestinal (GI) tract to treat bile duct...

Webinar Addresses ‘Hot Topic’

The recent OR Today webinar “Human Factors and Quality Testing for Device Reprocessing” was sponsored by Healthmark and eligible for one (1) continuing education (CE) hour by the State of California Board of Registered Nursing. The 60-minute webinar featured Jahan...

Nihon Kohden Introduces First Subscription-Based Pricing for Patient Monitoring, Neurology Products

Nihon Kohden, a U.S. market leader in precision medical products and services, has launched subscription-based pricing models for its patient monitoring and neurology products, the first in the industry to take such a step. The pricing models help align costs with...

Nihon Kohden Launches Life Scope SVM-7200 Series

Nihon Kohden has announced the launch of its Life Scope SVM-7200 Series vital signs monitor, a monitor designed for outpatient facilities and beds that traditionally are not continuously monitored. The monitor allows health care practitioners to quickly and easily...

ETS Wound Care Gains FDA Clearance for MIRRAGEN Advanced Wound Matrix

ETS Wound Care LLC, an Engineered Tissue Solutions (ETS) subsidiary focused on commercializing next generation wound care solutions, has announced that MIRRAGEN Advanced Wound Matrix was cleared by the United States Food and Drug Administration (FDA) for treatment of acute and chronic wounds. MIRRAGEN is a fully resorbable borate glass matrix comprised of fibers and beads proven to be highly effective in wound care management.

MIRRAGEN represents a breakthrough discovery for chronic and acute wound management due to its unique borate-based fiber matrix. MIRRAGEN is packed into wounds to manage and control wound fluids, while the resorbable matrix provides an environment for optimal wound healing. To learn more about the technology, click here.

“Anyone who is treating or experiencing discomfort from acute or chronic wounds will immediately recognize the benefits of MIRRAGEN,” said Peggy Earl, BSN, RN, WOCN, a wound care specialist at Phelps County Regional Medical Center located in Rolla, Missouri. “MIRRAGEN has the potential to reduce the required number of episodes and duration of wound care treatment, while allowing the body to effectively heal a variety of wounds, both acute and chronic.”

“The recent FDA approval is a significant milestone for ETS,” said Chad Lewis, PhD, ETS Wound Care President & CEO. “ETS Wound Care is pioneering an entirely new therapeutic option for wound care. The MIRRAGEN Advanced Wound Matrix is the first product utilizing our innovative borate fiber technology engineered to improve patient outcomes.”

ETS Wound Care plans to make MIRRAGEN commercially available via a controlled domestic market release in early Q2 2017 and available to the broader domestic market in 2018. Later this week, the company will be an exhibitor at the Nation’s largest interdisciplinary wound care forum – the Symposium on Advanced Wound Care Spring meeting (SAWC Spring) from April 6-8, 2017 in San Diego. Additional product information will be available at the ETS Wound Care exhibit booth (#602).

 

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X